Summary
Background
Sporadic duodenal cancer is a rare cancer entity. Therefore, the prognostic significance of clinicopathologic features is unknown. This study aimed to identify prognostic factors and compare survival with other tumour entities of the same anatomical region.
Methods
We retrospectively studied medical records of 22 patients with duodenal adenocarcinoma (DAC), who underwent resection in two German centres for pancreatic surgery (1994–2012). Mean time of follow-up was 51.3 months. Predictive factors were evaluated by log rank analysis.
Results
Whipple surgery was performed in seven cases (31.8 %), pylorus preserving pancreaticoduodenectomy in 14 cases (63.6 %) and partial duodenectomy in one case (4.5 %). R0-resection was achieved in 86.4 %. In all, 50% of our patients had nodal positive disease. Overall morbidity was 59.1 % and perioperative mortality was 9.1 %. Survival after resection was 63.6 % and 59.0 % (3- and 5-years). There was no significant survival difference between patients with DAC and ampullary cancer, but survival was longer compared with patients with pancreatic cancer.
Conclusions
Mortality seems to be high after resection of DAC. However, radical surgery should be performed due to the high number of patients with nodal positive disease. No definite prognostic factors were identified. The prognosis after resection of duodenal cancer can be compared with patients with ampullary cancer.
Similar content being viewed by others
References
Sexe RB, Wade TP, Virgo KS, Johnson FE. Incidence and treatment of periampullary duodenal cancer in the U.S. veteran patient population. Cancer. 1996;77(2):251–4.
Ouriel K, Adams JT. Adenocarcinoma of the small intestine. Am J Surg. 1984;147(1):66–71.
Hurtuk MG, Devata S, Brown KM, Oshima K, Aranha GV, Pickleman J, et al. Should all patients with duodenal adenocarcinoma be considered for aggressive surgical resection? Am J Surg. 2007;193(3):319–24.(discussion 324–5).
Sohn TA, Lillemoe KD, Cameron JL, Pitt HA, Kaufman HS, Hruban RH, et al. Adenocarcinoma of the duodenum: factors influencing long-term survival. J Gastrointest Surg. 1998;2(1):79–87.
Dabaja BS, Suki D, Pro B, Bonnen M, Ajani J. Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer. 2004;101(3):518–26.
Swartz MJ, Hughes MA, Frassica DA, Herman J, Yeo CJ, Riall TS, et al. Adjuvant concurrent chemoradiation for node-positive adenocarcinoma of the duodenum. Arch Surg. 2007;142(3):285–8.
Santoro E, Sacchi M, Scutari F, Carboni F, Graziano F. Primary adenocarcinoma of the duodenum: treatment and survival in 89 patients. Hepatogastroenterology. 1997;44(16):1157–63.
Kaklamanos IG, Bathe OF, Franceschi D, Camarda C, Levi J, Livingstone AS. Extent of resection in the management of duodenal adenocarcinoma. Am J Surg. 2000;179(1):37–41.
Lee HG, You DD, Paik KY, Heo JS, Choi SH, Choi DW. Prognostic factors for primary duodenal adenocarcinoma. World J Surg. 2008;32(10):2246–52.
Lee SY, Lee JH, Hwang DW, Kim SC, Park K-M, Lee Y-J. Long-term outcomes in patients with duodenal adenocarcinoma. ANZ J Surg. 2013.
Han S-L, Cheng J, Zhou H-Z, Zeng Q-Q, Lan S-H. The surgical treatment and outcome for primary duodenal adenocarcinoma. J Gastrointest Cancer. 2010;41(4):243–7.
Cecchini S, Correa-Gallego C, Desphande V, Ligorio M, Dursun A, Wargo J, et al. Superior prognostic importance of perineural invasion vs. lymph node involvement after curative resection of duodenal adenocarcinoma. J Gastrointest Surg. 2012;16(1):113–20. (discussion 120).
Onkendi EO, Boostrom SY, Sarr MG, Farnell MB, Nagorney DM, Donohue JH, et al. 15-year experience with surgical treatment of duodenal carcinoma: a comparison of periampullary and extra-ampullary duodenal carcinomas. J Gastrointest Surg. 2012;16(4):682–91.
Malleo G, Tonsi A, Marchegiani G, Casarotto A, Paiella S, Butturini G, et al. Postoperative morbidity is an additional prognostic factor after potentially curative pancreaticoduodenectomy for primary duodenal adenocarcinoma. Langenbecks Arch Surg. 2013;398(2):287–94.
Struck A, Howard T, Chiorean EG, Clarke JM, Riffenburgh R, Cardenes HR. Non-ampullary duodenal adenocarcinoma: factors important for relapse and survival. J Surg Oncol. 2009;100(2):144–8.
Rose DM, Hochwald SN, Klimstra DS, Brennan MF. Primary duodenal adenocarcinoma: a ten-year experience with 79 patients. J Am Coll Surg. 1996;183(2):89–96.
Sarela AI, Brennan MF, Karpeh MS, Klimstra D, Conlon KCP. Adenocarcinoma of the duodenum: importance of accurate lymph node staging and similarity in outcome to gastric cancer. Ann Surg Oncol. 2004;11(4):380–6.
Distler M, Rückert F, Hunger M, Kersting S, Pilarsky C, Saeger H-D, et al. Evaluation of survival in patients after pancreatic head resection for ductal adenocarcinoma. BMC Surg. 2013;13:12.
Rückert F, Kersting S, Fiedler D, Distler M, Dobrowolski F, Pilarsky C, et al. Chronic pancreatitis: early results of pancreatoduodenectomy and analysis of risk factors. Pancreas. 2011;40(6):925–30.
Wente MN, Veit JA, Bassi C, Dervenis C, Fingerhut A, Gouma DJ, et al. Postpancreatectomy hemorrhage (PPH): an International Study Group of Pancreatic Surgery (ISGPS) definition. Surgery. 2007;142(1):20–5.
Wente MN, Bassi C, Dervenis C, Fingerhut A, Gouma DJ, Izbicki JR, et al. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2007;142(5):761–8.
Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izbicki J, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery. 2005;138(1):8–13.
Kleinerman J, Yardumian K, Tamaki H. Primary carcinoma of the duodenum. Ann Intern Med. 1950;32:451–65.
Sarma DP, Weilbaecher TG. Adenocarcinoma of the duodenum. J Surg Oncol. 1987;34(4):262–3.
Rückert F, Pilarsky C, Grützmann R. Serum tumor markers in pancreatic cancer-recent discoveries. Cancers (Basel). 2010;2(2):1107–24.
Grützmann R, Rückert F, Hippe-Davies N, Distler M, Saeger H-D. Evaluation of the International Study Group of Pancreatic Surgery definition of post-pancreatectomy hemorrhage in a high-volume center. Surgery. 2012;151(4):612–20.
Allema JH, Reinders ME, van Gulik TM, Koelemay MJ, Van Leeuwen DJ, de Wit LT, et al. Prognostic factors for survival after pancreaticoduodenectomy for patients with carcinoma of the pancreatic head region. Cancer. 1995;75(8):2069–76.
Neoptolemos JP, Stocken DD, Dunn JA, Almond J, Beger HG, Pederzoli P, et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg. 2001;234(6):758–68.
Jabbour SK, Mulvihill D. Defining the role of adjuvant therapy: ampullary and duodenal adenocarcinoma. Semin Radiat Oncol. 2014;24(2):85–93.
Author information
Authors and Affiliations
Corresponding author
Additional information
P. Téoule and M. Distler contributed equally.
Rights and permissions
About this article
Cite this article
Téoule, P., Distler, M., Niedergethmann, M. et al. Retrospective analysis of prognostic factors in patients with duodenal adenocarcinoma. Eur Surg 48, 228–234 (2016). https://doi.org/10.1007/s10353-015-0374-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10353-015-0374-0